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Abstract
The tumor suppressor gene p53 is mutated or deleted in over 50% of human tumors. As functional p53 plays a pivotal role
in protecting against cancer development, several strategies for restoring wild-type (wt) p53 function have been
investigated. In this study, we applied an approach using gene repair with zinc finger nucleases (ZFNs). We adapted a
commercially-available yeast one-hybrid (Y1H) selection kit to allow rapid building and optimization of 4-finger constructs
from randomized PCR libraries. We thus generated novel functional zinc finger nucleases against two DNA sites in the
human p53 gene, near cancer mutation ‘hotspots’. The ZFNs were first validated using in vitro cleavage assays and in vivo
episomal gene repair assays in HEK293T cells. Subsequently, the ZFNs were used to restore wt-p53 status in the SF268
human cancer cell line, via ZFN-induced homologous recombination. The frequency of gene repair and mutation by non-
homologous end-joining was then ascertained in several cancer cell lines, using a deep sequencing strategy. Our Y1H
system facilitates the generation and optimisation of novel, sequence-specific four- to six-finger peptides, and the p53-
specific ZFN described here can be used to mutate or repair p53 in genomic loci.
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Introduction
The tumor suppressor p53 serves as a ‘‘guardian of the genome’’
[1] and has been studied intensively for over 30 years. By
responding to cellular stresses, such as DNA damage, hypoxia and
cell-cycle aberrations, p53 is activated as a transcription factor.
p53 can thus help to promote the repair and survival of damaged
cells by inducing cell-cycle arrest, or it can promote the permanent
removal of damaged cells by inducing programmed cell death or
senescence [2].
As the p53 gene is either mutated or deleted in more than 50% of
human tumors [3], functional p53 is very important in protecting
against cancer development. The vast majority of p53 mutations in
human tumors are single missense mutations that cluster in the core
DNA-binding domain of the protein (residues 100–300). This leads
to both the disruption of normal p53 function and the accumulation
of high levels of mutant p53 with various gain-of-function activities
(reviewed in [4,5]). Since tumors with mutant p53 often present
increased chemo- and radio-resistance, mutant p53 is an appealing
molecular target for tumor suppression. Moreover, the restoration
of p53 function is considered an important issue in cancer therapy
[6,7,8]. Several therapeutic strategies have therefore been pursued,
including expressing wt-p53 in gene therapy, eliminating mutant
p53 cancer cells with adenovirus, and directly restoring normal
function with small molecules that alter mutant p53 conformation
(reviewed in [9]).
Despite p53 being a desirable target, we currently lack the
necessary tools to carry out the most direct approach: to modify
genomes at will at disease loci like p53. Therefore we set out to
develop just such a strategy, using a recently-developed technology:
zinc finger nucleases (ZFNs). Since the first seminal publications
about ZFN fusions in the late 1990s [10,11,12], these artificial
proteins have promised to deliver a wide range of genome
engineering tools (reviewed in [13,14]). The beauty of this approach
is that zinc fingers are easily re-engineered to bind a wide variety of
DNA sequences (reviewed in Ref. [15]). Thus, ZFNs effectively
allow a type of ‘genome sculpting’ where externally provided DNA
can be recombined precisely into a genome [16], resulting in site-
specific gene repair, mutation, insertion or deletion.
ZFN gene targeting was first illustrated in the case of a mutant
Drosophila yellow gene [17,18] and has since resulted in a whole
field of engineering ZFNs. Examples include targeting disease loci,
such as IL2RG (mutated in severe combined immunodeficiency;
SCID-X1), where first gene repair [19], and then exogenous gene
integration [20] were achieved. ZFNs have also targeted genes in
model organisms such as C. elegans and Drosophila [21,22,23],
zebrafish [24,25,26], mouse [27], and plants [28,29,30,31,32].
The technology has been extended to mammalian systems such as
stem cells [33,34,35], the induction of cellular HIV resistance
[36,37,38] and even whole rat knockouts [39,40].
The specificity of ZFNs depends on artificially-engineered
DNA-binding domains: multi-zinc finger arrays that recognise
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long DNA sequences. There exists a large body of work on zinc
finger engineering (reviewed in [15]). Briefly, the established
engineering methods (amongst others) range from rational design
[41], modular assembly with pre-made fingers [42,43,44],
overlapping finger assembly [45,46] and bacterial-two hybrid [47].
A recent development is the emergence of two publically-
available sources of zinc fingers, the academic Zinc Finger
Consortium (ZFC; www.zincfingers.org) and the commercially-
available CompoZr, offered by Sigma Aldrich [48]. In particular,
the ZFC has provided a variety of open source tools for the
community to employ [49,50,51,52].
Although both sources facilitate obtaining ZFNs, these have to
be tested on a case-by-case basis for in vivo functionality, and
suboptimal candidates often have to be abandoned because of a
lack of straightforward optimisation protocols. Whereas screening
systems exist for 1- to 2-finger libraries (e.g. phage display) and 3-
finger mini-libraries of pre-selected modules (B2H [47]), no
straightforward system exists to optimize the 4- to 6-finger type
scaffolds which are provided by Sigma.
In this study, we set out to target the p53 gene using paired 4-
finger ZFN [19], and to develop a platform for optimising poly-
finger constructs. Because we found that classical phage display
could not handle .3-fingers (4-finger fd phage display always
resulted in truncations during selection; data not shown), we
modified a commercially-available yeast one-hybrid kit to optimize
such libraries . This was used to generate functional ZFNs against
two different sites (one exonic, one intronic) located within the
human p53 gene, in close proximity to the mutation hotspots of
p53 in somatic cancers (Fig. 1).
Results
Yeast one-hybrid selection of zinc fingers against two loci
in the human p53 gene
One-hybrid screening in yeast is a powerful method to rapidly
identify DNA-binding peptides that can interact with a specific DNA
sequence of interest. We therefore developed a yeast one-hybrid
(Y1H) selection system for zinc finger peptides, based on the
commercially-available Matchmaker Kit (Clontech). The system
allowed us to construct semi-randomised zinc finger libraries by
PCR (without cloning), and to screen them in one step, by yeast
transformation and plating on selective medium (Fig. 2).
We constructed four zinc finger libraries against two sites in the
human p53 gene (with two sub-sites L/R each for a functional
ZFN configuration; see Fig. 1B,C). The libraries were rationally
designed, based on the established protein-DNA recognition code
[53] and previously successful library designs [46]. Thus, the
libraries were randomized at several base-contacting positions in
the alpha-helix domains of the zinc fingers (library designs and
randomisation strategy are listed in Methods S1). The four-
finger library cassettes were built from degenerate oligonucleo-
tides, via a PCR-based construction [54], and were transformed
directly into yeast, together with linearized ‘‘prey plasmid’’
(pGADT7-Rec2) and the ‘‘bait plasmids’’ with the target DNA
sequences (Fig. 2B). The system exploits the high rate of
recombination in yeast to bypass standard cloning and to allow
the PCR library to fuse in frame with the prey vector, in the
single selection step.
A further modification to the Y1H, that we found to be essential
for selecting ZFP, was that the library cassettes had to be
introduced N-terminal to the Gal4-AD, rather than C-terminal as
in the Matchmaker kit (Clontech)(An example of a PCR cassette,
complete with homology arms, ready for transformation into yeast
is provided in Methods S1). The new configuration reduces the
number of false positive clones arising from truncated peptides
binding to the target sites; N-terminal truncations result in
frameshifts or deletion of the Gal4-AD, in most cases.
To create the ‘‘bait plasmids’’, the target DNA sequences for the
four ZFNs z771L, z771R, z1166L and z1166R) were cloned in
single copies, upstream of a minimal promoter controlling the
HIS3 reporter gene (Fig. 1C and 2). Successful application of any
Y1H system is constrained by requiring low recognition of the
target sequence by endogenous transcription factors. However, the
basal expression of the His3 protein, in the absence of an
activating prey protein, can be repressed by using 3-AT (a
competitive inhibitor of the His3 enzyme) [55]. Thus, in the
presence of increasing amounts of 3-AT, more His3 needs to be
expressed to confer growth and so the selection pressure can be
fine-tuned. Before screening the libraries, we tested each target site
for basal histidine expression in the absence of activating zinc
finger proteins. The amount of 3-AT needed to fully suppress
basal expression varied between 25mM (z1166L) and 75mM
(z771L, z771R, z1166R). Consequently, 100–150 mM 3-AT was
used for screening the libraries for DNA-binding ZFP. It is worth
noting that, classically, Y1H uses chromosomal integration of the
bait plasmid to reduce basal expression. However, the Clontech kit
uses low-copy-number plasmids to obviate this need (Clontech
Protocol No. PT3529-1).
To interrogate the zinc finger libraries in our Y1H assay, they
were co-transformed as PCR products, together with linearized
prey plasmids and bait plasmids, into the yeast strain Y187, as
described in the manual of the Matchmaker Kit (Clontech).
Transformations were plated on selection media containing 3-AT
and lacking histidine, tryptophan and leucine. The number of
screened clones per library was calculated according to the manual
of the Matchmaker Kit (Clontech) and was typically 100 000–
160 000 for each experiment. After incubation for 3–5 days at
30uC, library screening revealed many potentially positive colonies
of various sizes (200 to 2000 colonies). Ultimately, 96 colonies were
picked for each library and were replated in a 96-well pattern, on
selection media containing 3-AT.
Although this workflow undersampled both the theoretical
library sizes (Methods S1) and potential positives, it was sufficient
to obtain potentially-functional ZFP in one transformation step,
starting from rational designs that had little or no activity in DNA
cleavage assays, such as those shown in Fig. 3. The next step was
therefore to test these candidates for ZFN cleavage activity.
In vitro cleavage of p53 target sites
To validate Y1H-based protein-DNA interactions, ZFP genes
were recovered from yeast colonies by PCR, while introducing a
T7 promoter for subsequent expression. After a PCR-based fusion
to the FokI domain, the full length ZFN candidates were expressed
in vitro and tested for specific cutting activity in an in vitro cleavage
assay (see Methods and Fig. S1). This approach allowed us to
identify several 4-finger anti-p53 ZFNs that bind and cleave their
palindromic target sites efficiently in vitro (z771L, 4 clones; z771R,
1 clone; z1166R, 3 clones; z1166L, 1 clone).
From these clones, the best ZFN were similarly tested in homo-
and heterodimer pairs, for cleaving either palindromic test sites or
full DNA target sites (in the configuration shown in Fig. 1C;
L = left; R= right). The L/L and R/R-homodimers only cut their
respective palindromic target sites but not the unspecific targets
(Fig. 3B; left panel). Conversely, the full heterodimer targets
(ts771 and ts1166) were cleaved only by the correct combination of
z771L/R or z1166L/R, respectively, showing that a full pair of
ZFN are required for cutting (Fig. 3B; right panel).
p53 Gene Repair with Zinc Finger Nucleases
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Episomal gene repair
To evaluate whether our potential p53-specific ZFNs (z771 and
z1166) could promote homologous recombination or gene repair
in vivo, they were first tested in a plasmid-based EGFP repair assay,
developed by the Cathomen lab [56] (Fig. 4A).
In this assay, a promoterless EGFP sequence, with lacZ gene
homology arm, is used to repair a 59-truncated (non-fluorescent)
EGFP gene, and the process is stimulated by cleavage with the
appropriate nuclease. The target plasmid harbors a 18-bp
recognition binding site for the meganuclease I-SceI, which serves
as a positive control, in combination with a target site for the anti-
p53 ZFNs, z771 or z1166. The system is thus designed to restore
EGFP expression by generating a lacZ-EGFP fusion protein upon
nuclease-induced homologous recombination. The expression of
the red-fluorescent protein DsRed-Express (REx), from a gene
cassette located on the repair plasmid, labels transfected cells [56].
To validate the efficiency of our ZFNs, we transfected HEK293T
cells with either target plasmid ‘‘ts771’’ or ‘‘ts1166’’, the repair
plasmid and the respective PGK-driven ZFN pairs z771L/R and
z1166L/R. 48 hours after transfection, the percentage of green and
red cells was assessed by flow cytometry (Fig. 4B). The GFP repair
assay revealed that the zinc finger nucleases showed the strongest
activity when expressed in appropriate pairs to form heterodimers.
The repair efficiencies approached that of the benchmark control,
the meganuclease I-SceI (z771L/R, 20.9%; z1166L/R, 24.5%;
I-SceI, 20%–25%).
Some gene repair was observed when z771L (12%) and z771R
(15%) were expressed alone, probably due to DNA-binding by one
ZFNmonomer, followed by non-specific FokI dimerisation. This was
only seen for the nucleases with stronger activity (e.g. z1166L alone
did not considerably activate HR). Recent advances in generating
obligate heterodimer ZFN have demonstrated that it is possible to
remove this activity [57,58], and we used such mutants in
downstream assays. Notably, the EGFP-background level in the
absence of a nuclease was relatively high, representing spontaneous
homologous recombination events in this episomal system (8.2% for
target plasmid ts771 and 6.4% for ts1166). Nonetheless, the nuclease-
induced signals were highly reproducible and statistically significant
(z771L/R, p,0.002; z1166L/R, p,0.001). Therefore this assay is a
good way of validating ZFN for cellular use.
Chromosomal targeting of p53 gene by ZFNs
To determine whether our custom built ZFNs would also work
on a genomic level, we transfected HEK293T cells with PGK-
driven ZFN expression vectors against the target sites z771 and
z1166, together with homology repair plasmids. Because p53
cancer mutations are localised to one region of hotspots (Fig. 1A),
repair plasmids covering the majority of hotspots could be
Figure 1. Zinc finger nucleases for the human p53 gene. (A) Mutation hotspots in somatic cancers from the IARC TP53 Mutation Database R13.
(B) Exons 5–8 from the p53 gene (Human Genome: NW_001838403) are highlighted in grey and contain nearly all mutation hotspots (underlined
black; codon number in brackets). ZFN binding sites are highlighted in black with white letters. (C) Canonical model of designed zinc finger nucleases
(z771 and z1166) against two target sites in the p53 gene. Arrows indicate possible base contacts. Zinc finger alpha helix sequences, involved in DNA
recognition, are indicated (F1, Finger 1, etc.).
doi:10.1371/journal.pone.0020913.g001
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Figure 2. Yeast one-hybrid based selection for ZFNs. (A) The ZF-target site is cloned upstream of a minimal promoter (Pmin) and the HIS3
reporter in the bait plasmid. Any interaction between a ZFP:Gal4-AD fusion protein and the target sequence stimulates transcription of HIS3 allowing
selection on His-selective medium (B) The ZF-library:Gal4-AD fusion is generated by yeast recombination of a PCR-generated four-finger library
cassette with the linearized prey plasmid; no extra library cloning step is required. Thus, bait plasmid, linearized prey plasmid and library PCR cassette
are co-transformed into yeast. After incubation for 3–5 days, expression from the HIS3 reporter is detected in colonies that are able to grow on a
selection medium that lacks histidine and contains 3-AT (see Methods). ZFP from positive clones are rescued by colony-PCR, are fused to a FokI-
domain and are tested for activity by an in vitro cleavage assay. (C) Zinc finger library PCR template (z1166L). The template is based on 262-finger
units from F2-F3 of the Zif268 sequence [65]. Each pair of 2-finger units is separated by a longer TGSERP linker [66]. The final linker, (QNKKQLVKSEL) is
compatible with the FokI sequence and is adapted from [16]. DNA-recognition helices are selectively randomised at certain positions (marked ‘‘X’’).
Full sequences and randomisation strategy are in Methods S1.
doi:10.1371/journal.pone.0020913.g002
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synthesised, containing either 1.35 kb or 1.78 kb DNA, homolo-
gous to the genomic p53 locus between exons 5–8 or 6–8
(Sequences given in Methods S1).
The donor plasmids contained modified sites in the target sites
of the z771- and z1166-ZFNs, to avoid cutting of the donor
plasmid by the respective ZFNs, and to allow detection of genomic
recombination of the plasmid by PCR analysis (Fig. 5). The latter
was achieved using external PCR primers to amplify the p53
genomic regions, followed by semi-nested PCR, with a forward
primer specific for the modified DNA sequence (‘‘barcode’’), and
an external genomic reverse primer. The modified barcodes in the
exonic target z1166 were carefully-chosen silent mutations that do
not alter the p53 amino acid sequence.
For analysis of genome editing, genomic DNA was prepared
from a pool of treated HEK293T cells, 3–6 days after transfection.
Targeted donor recombination at the p53 locus was demonstrated
by semi-nested PCR (Fig. 5B). Both ZFN-pairs were able to
induce recombination of the donor plasmid with the chromosomal
p53 gene, whereas control cells, transfected only with donor
plasmid (and an empty PGK expression vector), did not show any
sign of donor plasmid recombination. Although ZFN-specific
recombination was seen with both repair matrices, the shorter
exon 6–8 donor plasmid gave the clearest results because we were
able to employ a particularly specific external genomic primer, just
at the start of exon 6. Therefore this donor plasmid was mainly
used in subsequent assays.
Next, we applied our z1166-ZFNs to induce the restoration of
wt-p53 status in the human glioblastoma cancer cell line SF268,
which harbors a single missense mutation (cgtRcat) at codon 273
in the core domain of p53 [59]. The SF268 cells were also
transfected with PGK-driven z1166-ZFN expression vectors and a
donor plasmid with wild type p53 sequence at codon 273. The
treated cells were analyzed by PCR, as described for the
HEK293T cells, and also showed site-specific recombination of
the donor plasmid with the p53 gene, only when co-transfected
with functional ZFNs (Fig. 5C).
As the point mutation in SF268 cells is located in exon 8,
approximately 450 bp downstream of z1166 target site, PCR
amplicons obtained with recombination-specific primers were
subcloned by Topo-TA cloning; 10 clones were sequenced to
check for downstream modification at the mutated R273H codon.
All the clones showed a restoration of the p53 wild-type sequence
Figure 3. In vitro cleavage of p53 zinc finger nucleases. (A) Schematic of palindromic- (pts) or heterodimer (ts) DNA target sites of z771 and
z1166 ZFNs. Both strands of DNA are shown with the top strand written 59 to 39 and the bottom strand written 39 to 59. The primary strand of the 12-
bp target sites is highlighted (ZFNs ‘771L’ and ‘1166L’ in light grey, ‘771R’ and ‘1166R’ in dark grey). (B) Analysis of homo- and heterodimer cleavage
reactions. In vitro expressed ZFNs were incubated with a linear target DNA substrate and cleavage products were analyzed by agarose gel
electrophoresis. Cleavage of the target DNA results in two DNA molecules of the same size, simplifying the analysis.
doi:10.1371/journal.pone.0020913.g003
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at codon position 273. This indicated that homology-directed
repair occurred .450 bp downstream of the ZFN-induced
double-stranded break (Fig. 5C, bottom). This result is perhaps
surprising, because 80% of gene conversion tracts in mammalian
cells are expected to be within 100 bp of the double-stranded
break [60]. Insertions can occur 400 bp away and further, albeit
with much lower frequency [61,62]. It was therefore possible that
the PCR amplicons did not reflect independent events, and so we
set out to measure the frequency of ZFN-induced homologous
recombination.
Measuring gense repair and non-homologous end-
joining by deep sequencing
Next generation sequencing is an ideal tool to quantify the effects of
ZFN on cells. Reads from genomic PCR-products can routinely give
.20 million sequences (,100 bp length) in a single run, and primer
barcoding can be used to mix different samples together, allowing
subsequent data deconvolution. We therefore developed a Solexa-
Illumina method to sequence p53 locus genomic PCRs, at the site
targeted by z1166. We thus measured the short insertions and
deletions caused by non-homologous end-joining (NHEJ), after a
nuclease-induced double-stranded break [25]. We also measured the
rate of ‘wt’ sequence insertion from a ‘barcoded’ donor plasmid (with
wild-type protein-coding sequence).
First, using 31bp reads, we observed NHEJ from ZFN in
HEK293T cells (Fig. 6A). The method involved 2 rounds of PCR:
one external genomic PCR and one internal PCR to introduce
3bp sequencing barcodes and anMmeI cleavage site (seeMethods
S1).MmeI digestion allowed sequencing-adapter ligation as close to
the region of interest as possible but, as a result, the method was
qualitative rather than quantitative. Nonetheless, the method
showed that ZFN treatment was required to observe insertions and
deletions around the genomic cutting site; these mutations can be
useful for knocking out genes [38,39].
Next, we carried out a series of experiments using an improved
protocol: 104bp read length was achieved using a Solexa Genome
Analyser IIx. After external genomic PCR, a second internal PCR
introduced a 3bp sequencing barcode; the longer read length
removed the need for MmeI digestion. Interestingly, we found that
the slightly higher error rate of the newer HiSeq Solexa machine
was suboptimal for this task, so the GA IIx was preferred. To
achieve high-quality long reads with highly-similar PCR products,
we found it was necessary to ‘spike’ the samples with random DNA
(phiX DNA fragments; 50% of total input DNA). In each flow cell
lane, after computationally filtering out phiX sequences, we were
able to get around 5 million sequences in the correct orientation
(,50%). We were thus able to mix up to 8 sequencing barcodes
per lane (each representing a different sample, under different
conditions), resulting in around 600 000 reads each.
Processing the data for measuring NHEJ required two steps.
First, the different barcoded samples were extracted using filters
for any sequences containing a 9bp prefix (with the 3bp unique
sequencing barcode) and a 9bp suffix (after the ZFP binding
site)(see Methods S1). Second, to reduce random sequencing
errors (proportional to read length), we filtered for the short
,30bp region spanning the cutting site (sequences containing a
Figure 4. Episomal gene repair assay in HEK293T cells. (A) Schematic representation of the experimental setup. (B) Cells transfected with
repair plasmid, target plasmid and ZFN expression vectors were analyzed after 48 hrs by flow cytometry. The diagram displays the fraction of EGFP-
positive cells normalized for transfection efficiency. Statistically significant increases in homologous recombination (HR), compared to non-induced
HR control (dashed grey line) are indicated with asterisks (** = p,0.0001 and * =p,0.002).
doi:10.1371/journal.pone.0020913.g004
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new 6bp prefix-suffix;Methods S1). The percentage of sequences
containing insertions or deletions was then calculated (Fig. 6B).
By testing different cancer cell lines (SF268, K562 and BT549) we
found that ZFN-dependent indels could be detected in all three,
but were much more frequent at 30uC (transient cold shock) than
at constant 37uC, as was recently reported [63]. Furthermore, we
could observe NHEJ with both wt and obligate heterodimer FokI
[57]. The increase in NHEJ signal with ZFN was up to 30-fold
over background, indicating that next generation sequencing can
be used reliably to measure this activity.
ZFN-driven gene repair was quantified in two human cancer
cell lines (SF268, and BT-549). The cell lines were either
transfected with z1166-ZFNs alone or with both ZFN and donor
plasmid (to quantify ZFN-induced homologous recombination).
First, the ability of the Solexa system to detect proportions of wt or
mutant DNA was tested; plasmid samples were mixed at ratios of
1:100 or 1:1000, and were then processed as if they were genomic
PCRs (Fig. 6C). The observed detection rate was indeed similar to
that expected, despite the PCR amplification and adapter ligation
steps during sample preparation. Next, a variety of constructs with
Figure 5. Targeted genomic recombination with p53 donor plasmid. (A) Schematic of the genomic p53 locus and the donor plasmid, with
modified DNA sequences at z771 and z1166 target sites (‘‘barcodes’’; highlighted in red). Barcodes allow selective PCR but do not change the p53
protein sequence. Black arrows indicate primers for genomic PCR that hybridize to the chromosomal p53 locus outside of the region corresponding
to donor sequence. (B) Targeted donor plasmid recombination into the p53 z771 and z1166 loci in HEK293T cells. ZFN-induced recombination is
shown by semi-nested PCR, on purified external genomic PCR template, with forward primers that discriminate between wild-type and barcode
sequence. (C) Targeted donor recombination at the p53 z1166 locus in human SF268 glioblastoma cells. (D) Restoration of p53 wild-type sequence at
codon 273 in ZFP-treated SF268 glioblastoma cells. The relative positions of the z1166 cutting site and codon 273 are indicated in Fig. 1B.
doi:10.1371/journal.pone.0020913.g005
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different promoter and FokI nuclease variants were tested for their
ability to induce homologous recombination (insertion of the
donor plasmid sequence)(Fig. 6D,E). The best results were
obtained with obligate heterodimer FokI nuclease [57], under a
PGK promoter. Collecting the genomic DNA 7 days after the
ZFN and donor plasmid transfection also helped to reduce
background (Sigma Aldrich; Compo-Zr instructions). Although
the absolute rates of homologous recombination are apparently
quite low (,0.1%), this is still an ,100-fold improvement over
background, indicating that the ZFN are functional at this locus.
In summary, we were able to use Y1H to engineer ZFN against
p53 chromosomal targets and were able to show their activity to
modify genomes at the selected loci.
Discussion
This study describes the development of a new yeast-based
selection tool for the rapid construction and optimization of paired
4-finger ZFN [19]. We developed the Y1H tool because we found
that our usual phage display system [46] did not work with more
Figure 6. Solexa-Illumina deep sequencing of ZFN-treated cells. (A) Short 31bp reads detect ZFN-induced non-homologous end-joining
(NHEJ) events in HEK293T cells. The FokI cutting region (CAACTA) is indicated in bold, deletions are shown with ‘‘-’’ and insertions are underlined.
(B) 104bp-read protocol: quantifying the rate of insertions and deletions induced by ZFN under a PGK promoter. SF268, K562 and BT549 cells were
kept at 37uC or subjected to transient cold shock to increase NHEJ (30uC; [63]). ZFN plasmid amounts (0, 1 and 1.5 mg) are indicated by -, + asnd ++,
respectively. Obligate heterodimer FokI mutants [57] are indicated where used (ObH). (C) Controls using wt:mutant plasmids at ratios of 100:1 and
1000:1. After mixing, samples were treated identically as for other Solexa samples (3bp-barcode PCR, adapter ligation etc.). The proportion of
wt:mutant sequence in the Solexa output was then calculated. (D) Quantifying the rate of insertion of a barcoded (wt coding sequence) donor
plasmid into the genomic p53 locus, in SF268 cells. CMV and PGK promoters were tested in combination with wt or ObH FokI nuclease domains. (E) A
similar gene repair experiment in BT549 cells. Genomic DNA was collected 7 days after ZFN and donor plasmid transfection, to reduce background.
doi:10.1371/journal.pone.0020913.g006
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than three fingers. Selections from 4-finger libraries resulted in
spontaneously-truncated variants with fewer fingers, via in-frame
homologous recombination in the bacterial host (data not shown).
The truncated proteins were likely preferentially encapsidated,
displayed and infected, and so 4-fingers are beyond the size limit
that can be conveniently selected on capsid gene III. Despite trying
different bacterial host strains, selection conditions, and even a
PCR-gel-purification step in between selection rounds (to recover
full-length clones), we were unable to overcome these issues. As
classical phage display could not handle more than 3-fingers, we
developed the yeast one-hybrid system, whose main advantage is
that it uses PCR libraries directly and does not require a bacterial
cloning step.
Our main motivation was to be able to screen relatively small
libraries (,100 000 variants), with mutations spread over four or
more fingers (the system works equally well for 6-finger proteins;
Fig. S3). Small, targeted libraries can easily be rationally
designed, given the 15 years of data on the zinc finger DNA-
recognition code [15,53]. Moreover, the Y1H system can also be
used for affinity maturation of ZFP; libraries can be made by
error-prone PCR and PCR-shuffling for this purpose, starting
from a single ZFP design.
The use of yeast-based selection has certain advantages over
phage display or prokaryotic expression systems (although the
latter allow larger library sizes). For instance, the strategy allows
the direct selection of peptides that are able to recognize DNA in
vivo, without disrupting an eukaryotic cell. Thus, an element of
screening for eukaryotic specificity and neutrality is added: the
yeast genomic DNA, which is assembled into chromatin, is more
repesentative of the final environment where the ZFN will be used.
Nonetheless, the selection is for DNA binding and not ZFN
cleavage; future engineering strategies could aim to select for
cleavage activity and specificity directly. For example, the ZFN
could cleave a target-DNA that is contiguous with a conditionally-
lethal gene in yeast, such as Herpes simplex virus-thymidine kinase
(HSV-TK) [64].
It should be noted that the quality of the screening is strongly
dependent on the library design. In three cases (z771L, z1166L and
R), the Y1H libraries produced functional ZFN that were much
better than the original rational designs, around which the libraries
were based. Indeed, in these cases, the single rational designs had no
activity in the in vitro cleavage assay, whereas Y1H clones had
demonstrable activity (Fig. 3). The exception was z771R, which
was rationally designed and functioned so well that no improve-
ments were obtained from Y1H. Typically, however, Y1H made
the difference between a functional or non-functional ZFN.
We generated novel functional 4-finger nucleases against two
sites located within the human p53 gene, in close vicinity to the
mutation hotspots of p53 in cancers. The uniqueness of the targets
in the genome was verified by a genome scanning algorithm that
we developed (Table S1). This showed that the z771 and z1166
target sites are unique, and that the z1166 binding site had very
few related targets in the human genome (only one 2bp mismatch
and eight 3bp mismatches, for the full heterodimer site). z771 had
slightly more related targets, but these are mostly in duplicated
intronic sequences. Intron sites are likely to be more tolerant of
indels from NHEJ, because no coding sequence is disrupted.
Furthermore, intron sites can still be used for exonic gene repair,
because homologous recombination can extend for hundreds of
bases beyond the double-stranded break.
Initially, expression of our ZFN constructs was driven by a
strong CMV promoter, but this was found to be suboptimal. It is
possible that high expression levels of the nucleases were not well
tolerated by the cells, probably leading to their elimination over
time through accumulation of non-specific double strand breaks
(Fig. S2) [56]. Alternatively, the CMV promoter expressing ZFN
could compete with the CMV-driven GFP reporter, decreasing
expression of both. For example, we observed that CMV-HcRed
plasmid, used as a transfection marker, had reduced activity when
co-transfected with other CMV-driven plasmids, but not with
PGK-driven plasmids. After optimisation, i.e. finding the right
promoter for ZFN expression (PGK), and adding a nuclear
localization signal to the ZFN, we were able to get a good
induction of GFP repair by both our anti-p53 ZFNs.
Using the Solexa protocol to quantify ZFN effects on the z1166
chromosomal locus, we confirmed that transient 30uC cold shock
[63] improves the rates of NHEJ. The different cell lines each had
different rates of NHEJ, and K562 had the highest. For gene
repair, the best results were obtained using obligate heterodimer
ZFNs [57], under a PGK promoter, and waiting for 7 days after
transfection to reduce background from left-over donor plasmid.
Although the apparent rates of homologous recombination are
quite low (,0.1%), the percentage of modified cells may actually
be higher, since both alleles will not be modified in all cases.
Moreover, for targeted mutation or repair experiments, the use of
selection genes (e.g. puromycin resistance), combined with these
low but workable recombination frequencies, should help to
establish model cell lines or organisms.
We have demonstrated that our p53-specific ZFNs are functionally
active chromosomally and can be used to mutate or restore wt-p53
status. Overall, this study has provided a Y1H tool to optimise ZFN,
as well as functional anti-p53 ZFN for biotechnological applications.
Materials and Methods
Cell lines and culturing
The wt p53 cell line HEK293T was maintained in DMEM and
the mutant p53 cell line SF268 (kindly provided by A. Carnero)
was cultured in RPMI1640 at 37uC, in 5% CO2. All media were
supplemented with 10% FCS, 100 units/ml penicillin and
100 mg/ml Streptomycin.
Yeast one-hybrid selection of p53 zinc-fingers
Four-finger library cassettes were constructed from oligonucle-
otides, using a PCR based construction approach (library designs
are listed in Methods S1). Two-finger units (F1-F2 and F3-F4)
were built from two oligonucleotides by overlapping primer
extension [54]. After amplification by PCR, introducing a BamHI
site at the 39-end of F1-F2 and a BglII site at the 59-end of F3-F4,
two-finger units were mixed, cut with BamHI and BglII and
conditionally ligated. The resulting four-finger library cassettes
(F1-F2-F3-F4) were amplified by PCR by using oligonucleotides
which added 59-and 39-homology arms for the prey plasmid
(sequences in Methods S1).
Target sequences were inserted into pHis2.1 bait plasmid
(Clontech), using 22bp duplex DNA oligomers. Each pair of
oligonucleotides was annealed to form duplex DNA, with EcoRI/
SpeI compatible overhangs, and ligated into EcoRI/SpeI-cut vector
pHis2.1.
pGADT7-Rec2 prey plasmid (Clontech Matchmaker One-
Hybrid Library Construction and Screening Kit; Ref. 630304)
was modified by removing a second HindIII site at 2351bp by
site directed mutagenesis. The PCR libraries were then
introduced into HindIII-linearized modified prey plasmid, by
in-frame recombination in yeast strain Y187. The yeast were
simultaneously heat-transformed with linearized prey plasmid,
PCR library and bait plasmid, according to the manufacturer’s
instructions.
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ZFPs with specific DNA-binding activities were recovered by
plating the yeast transformations onto selective SD medium.
Colonies growing on SD medium lacking histidine, tryptophan
and leucine, but supplemented with 100mM or 150 mM 3-amino-
1,2,4-triazole (3-AT), were replated on the same medium. ZFP
genes were extracted from yeast by colony PCR (KOD
polymerase; 2mM Mg; initial lysis at 98uC, 8 min) followed by a
nested PCR to introduce a T7 promoter for protein expression in
a TnT T7 Quick for PCR DNA kit (Promega). The coding
sequence for the FokI-nuclease domain was fused in frame, via
PCR, to create functional ZFNs (Fig. S1). All primers and
conditions are indicated in Methods S1. The activity of the
resulting ZFNs was verified by an in vitro DNA cleavage assay (see
below).
Zinc finger nuclease constructs and plasmids
ZFN coding sequences were cloned into BamHI/SalI cut plasmid
pPGK.GZF1-N (gift from Toni Cathomen) [58]. To create ZFN of
the high-fidelity obligate heterodimer type [57], we introduced point
mutations in FokI using the QuickChange mutagenesis kit (Invitro-
gen). The nuclease expression vector pRK5.LHA-SceI, the repair
plasmid pUC.Zgfp/Rex and the target plasmid pCMV.lacZsdGFP
‘‘0-0’’ have been described before [56]. The target plasmids
pTARGET-771, pTARGET-1166 and palindromic target plasmids
pTARGET-pts771L, pTARGET-pts771R, pTARGET-pts1166L,
pTARGET-pts1166R were created by adding additional binding
sites for the respective ZFNs. Two complementary synthetic 39-mer
oligonucleotides were annealed and cloned into the PacI site of
pCMV.lacZsdGFP ‘‘0-0’’ to generate each of the target sequences
indicated in Fig. 1B,C and Fig. 2A. The ZFN target sites in each
construct were verified by DNA sequencing.
In vitro DNA cleavage assay
A 154bp linear target DNA was amplified by PCR from
pTARGET plasmids with primers Target_seqL1 (59-accagttggtctggtgt-
caa-39) and Target_seqR1 (59-ctgaacttgtggccgtttac-39). DNA templates
for in vitro expression of ZFNs were amplified by PCR from positive
yeast colonies or from ZFN expression vectors using primers
T7kozak_FWD (59-tcgagtaatacgactcactatagggagaaacaccatagattgccatg-
gccgagcgccccttc-39) and UnivQQR_R_NotI (59-aaggaaaaaagcggccg-
caaaaggaaaaggatcctcattaaaagtttatc-39). All PCR reactions were puri-
fied with the QiaQuick PCR Purification Kit (Qiagen).
The ZFNs were expressed from 100ng T7-PCR templates, using
the TnT-Quick coupled transcription-translation system (Promega),
according to the manufacturer’s protocol, except that ZnCl2 was
added to a final concentration of 4 mM. To analyze ZFN activities,
TnT reactions were mixed with 200 ng of target DNA and diluted
with FokI cleavage buffer to a final concentration of: 20 mM Bis-
Tris-propane pH 7.0, 100 mM NaCl, 5mM MgCl2, 0.1 mM
ZnCl2, 5 mM DTT, 1.8% (vol/vol) glycerol, 20 ug/ml poly-d(I-
C), 0.1 mg/ml BSA. After incubation for 5–6 hrs at 30uC, the
reactions were cleaned with a PCR Purification Kit (Qiagen) or,
alternatively, were treated with 1 ml RNase A (10 mg/ml, Qiagen)
for 30 minutes at 37uC and 1 ml Proteinase K (20 mg/ml, Qiagen)
for 1 hour at 37uC. Samples were then analysed on a 1.8% agarose
gel, with ethidium bromide staining.
Episomal gene repair assay
For episomal gene repair, we typically followed the protocol
described in [56]. Briefly, HEK293T cells in 24-well plates were
transfected by Lipofectamine 2000 (Invitrogen) with 100 ng of
target plasmid, 300ng of repair plasmid pUC.Zgfp/REx or repair
control pUC.REx, and 100ng of PGK-driven ZFN expression
vectors, I-SceI (pRK5.LHA-SceI) or control vector pUC19. The
amount of DNA was kept constant by adding pUC19 to 500ng.
After 48 hrs, 56105 cells were analyzed by flow cytometry
(FACSCanto, BD Bioscience) to determine the percentage of
EGFP- and REx-positive cells. Statistical significance was
determined using the Student t-test. Error bars in figures are
one standard error based on three biological replicates.
PCR analysis of genomic recombination of p53-donor
plasmid
26106 K562 cells were transfected with 5 mg of each ZFN
expression construct, and 10 mg of the donor plasmid, using the
single-cuvette format of the Nucleofector Kit V (Lonza),
according to the manufacturer’s protocol. HEK293T, SF268,
and BT-549 cell lines were transfected in 6-well plates by
Lipofectamine 2000 (Invitrogen), with 5 mg repair matrix donor
plasmid, and 2 mg of ZFN expression vectors, or empty control
vector. An EGFP expression vector (0.5 mg) was cotransfected
in all the samples (except K5652 cells) to identify transfected
cells. Six days after transfection, 16105 GFP-positive cells per
sample were collected by fluorescence activated cell sorting
(FACS) and genomic DNA was isolated from cells with the
DNA Blood and Tissue Kit (Qiagen). To detect homologous
recombination in the p53 gene, we subjected 30–300 ng
genomic DNA to PCR with high fidelity enzymes KOD Hot
Start (Novagen) or Accuprime Taq DNA Polymerase (Invitro-
gen). PCR products were column purified with the PCR
purification kit (Qiagen) and eluted in 30 ml H20. A fraction of
the resulting amplicons was amplified by nested PCR with Taq
polymerase using primers designed to discriminate between
wild-type and integrated modified p53 sequence. Nested PCR
amplicons were resolved on a 1.5% agarose gel and visualized
by ethidium bromide staining. All primers and conditions are
indicated in Methods S1.
Quantification of non-homologous end-joining and
homologous recombination events
The frequency of targeted gene modification in ZFN-treated
pools of cells was determined by Illumina’s Solexa deep
sequencing platform. Transfections, genomic DNA preparation
and PCR reactions were performed as described above. PCR
products were excised from agarose gels, to avoid contamination
with transfected donor plasmid, were column purified with a PCR
purification kit (Qiagen) and eluted in 30 ml H20. 10 ng of the
PCR products were amplified by nested PCR with KOD HiFi
polymerase, with Solexa primers flanking the 1166 target region
(,90bp up- or down-stream). The primers contained 3bp
barcodes in order to distinguish between individual samples in a
pooled Solexa lane. PCR amplicons were column purified for
sequencing adapter ligation with Illumina protocols.
Illumina sequencing and basecalling
PCR products that contained single-read Solexa adapters on
either end were mixed 1:1 with a phiX Solexa library (Illumina).
Single-read v4 flowcells for the Genome Analyzer were used. After
loading DNA at a concentration of 7 pM per flow cell lane,
clusters were generated in the Illumina cluster station according to
the recommendation of the manufacturer. Sequencing was
performed on the Illumina Genome Analyzer IIx with TrueSeq
SBS v5 sequencing chemistry, using a 104 cycle recipe. Basecalling
was performed using SCS2.8. Primers and conditions and
computational filters used for data processing are indicated in
Methods S1.
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Supporting Information
Figure S1 Experimental scheme to validate yeast one-
hybrid clones. Assembly PCR was used to recover zinc finger
sequences from positive yeast colonies and to fuse them to a FokI
nuclease domain and T7 promoter, for in vitro transcription-
translation expression (TnT). Clones marked with an asterisk
showed clear cleavage activity of the target DNA (palindromic
target site). These positives were subcloned for further verification.
(TIF)
Figure S2 ZFN-associated toxicity assay. Flow cytometry
data for HEK293T cells transfected with the indicated constructs
and stained with antibodies against gH2A.X (top) or unspecific
staining-control antibodies (bottom). The columns show the
percentage of gH2A.X-positive cells normalized for transfection
efficiency. Overall, pPGK constructs had lower toxicity than
pCMV constructs, although the meganuclease I-SceI had even
lower toxicity. Etoposide is a toxic positive control.
(TIFF)
Figure S3 Six finger peptides engineered by Y1H for the
GFP DNA sequence. (A) Canonical model of ZFP binding,
where primary DNA contacts (arrows) are from four positions on
each zinc finger alpha helix (circled, 21, 2, 3 and 6). Contacts
shown are for the EGFP gene-binding construct, ZFP_GFPb249.
(B) List of ZFPs engineered against the EGFP coding sequence
(ZFP_GFPb249). The alpha helices are shown aligned to the DNA
bases they would contact according to the canonical model. Note
that zinc finger proteins (N-C) bind antiparallel to their primary
contacting DNA strand (39-59). (C) Gel shift assays on ZFPs
expressed in vitro from T7-promoter PCR products show that the
2 ZFPs bind their DNA targets.
(TIFF)
Table S1 Putative off-target sites. The number of occur-
rences (in the human genome) of sequences related to the target
sequence were counted with a computer script written in C. For
example, there are 35 sequences with 2 bases different from the
full z771 zinc finger binding site (bs771). Overall, the z1166
binding site has fewer related targets in the human genome.
bs = binding site. pts = palindromic target site. The different left-
and right-finger binding sites are highlighted in bold or normal
font, respectively.
(DOCX)
Methods S1 Supplementary methods and sequences.
This document contains sequence templates and instructions for
inserting zinc finger DNA sequences into the yeast 1-hybrid
template. Strategies for selective codon randomisation are
discussed. The sequences for the zinc finger libraries, final clones
and donor plasmid sequences used in this study are also provided.
Protocols for Solexa sequencing of ZFN genomic targets are
described, as well as protocols for measuring double-stranded
DNA breaks.
(DOC)
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